{"id":"aminosalicylic-acid-resin-complex","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acidosis","Anemia due to enzyme deficiency","Chronic heart failure","Cobalamin deficiency","Crystalluria","Deficiency of glucose-6-phosphate dehydrogenase","Disease of liver","Duodenal ulcer disease","Gastric ulcer","Goiter","Hypokalemia","Kidney disease","Peptic ulcer"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"approved","trials":["NCT02683733","NCT00042289","NCT03804931","NCT06013696","NCT03237182","NCT01586533","NCT01612247","NCT04499495","NCT05663775","NCT03070574","NCT04034758","NCT00000796","NCT01320436","NCT01020708","NCT00514982","NCT06895252","NCT00513396","NCT02537210","NCT01941589","NCT03980405","NCT00417690","NCT00004810","NCT02365623","NCT00004423","NCT01004185","NCT02930343","NCT02128308","NCT05213234","NCT07296315","NCT04032652","NCT06213857","NCT03070405","NCT01654783","NCT01577966","NCT00069498","NCT05610956","NCT05988528","NCT01532648","NCT02077777","NCT06998693","NCT00495521","NCT05986136","NCT00984568","NCT02975570","NCT06201793","NCT01090102","NCT06081361","NCT01860963","NCT07389824","NCT03625739"],"aliases":[],"company":"BRISTOL MYERS SQUIBB","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AMINOSALICYLIC ACID RESIN COMPLEX","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:54:45.551093+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:54:59.597986+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:54:51.217506+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMINOSALICYLIC ACID RESIN COMPLEX","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:54:51.620721+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Dihydrofolate reductase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:54:53.068158+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1169/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:54:52.736853+00:00"}},"allNames":"rezipas","offLabel":[],"timeline":[],"aiSummary":"REZIPAS, also known as 4-Aminosalicylic acid, is a small molecule dihydrofolate reductase inhibitor. It has been studied in clinical trials for various conditions, including Ulcerative Colitis, HIV Infections, and Sexually Transmitted Diseases, often in comparison to Budesonide MMX or Placebo.","brandName":"REZIPAS","ecosystem":[],"mechanism":{"target":"Tyrosine-protein phosphatase non-receptor type 1, Cyclooxygenase, 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase","novelty":"","modality":"Small Molecule","drugClass":"","explanation":"","oneSentence":""},"commercial":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:54:59.598088+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://www.fda.gov/drugs","name":"FDA Drugs@FDA","fields":["phase","status","brandName","company"],"retrievedDate":"2026-04-07"},{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"AMINOSALICYLIC ACID RESIN COMPLEX","indications":{"approved":[{"name":"Acute tuberculosis","diseaseId":"acute-tuberculosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pulmonary tuberculosis","diseaseId":"pulmonary-tuberculosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"BRISTOL MYERS SQUIBB","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02683733","phase":"Phase 3","title":"The Efficacy and Tolerability of Bio-enhanced Curcumin (Diferuloylmethane) in the Induction of Remission in Patients With Mild to Moderate Ulcerative Colitis","status":"UNKNOWN","sponsor":"Asian Institute of Gastroenterology, India","isPivotal":true,"enrollment":50,"indication":"Ulcerative Colitis","completionDate":""},{"nctId":"NCT00042289","phase":"N/A","title":"Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":1578,"indication":"HIV Infections","completionDate":"2020-09-30"},{"nctId":"NCT03804931","phase":"Phase 2","title":"Efficacy and Safety of Fecal Microbiota Transplantation for Ulcerative Colitis","status":"RECRUITING","sponsor":"Guangzhou First People's Hospital","isPivotal":true,"enrollment":120,"indication":"Ulcerative Colitis, Fecal Microbiota Transplantation","completionDate":"2030-12-31"},{"nctId":"NCT06013696","phase":"NA","title":"The Effect of Household Bleach on Urine Color Among Pediatric Ulcerative Colitis Patients Treated With 5-aminosalicylic Acid","status":"UNKNOWN","sponsor":"Meir Medical Center","isPivotal":false,"enrollment":40,"indication":"Ulcerative Colitis","completionDate":"2024-12"},{"nctId":"NCT03237182","phase":"Phase 4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study A Strategy to Improve Treatment Outcomes in Patients With Drug-resistant TB","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","isPivotal":false,"enrollment":205,"indication":"Tuberculosis, Multidrug-Resistant","completionDate":"2022-12-19"},{"nctId":"NCT01586533","phase":"Phase 2","title":"A Phase II Double-blind, Randomized, Comparator-controlled Study of the Safety and Efficacy of Zoenasa™ Rectal Gel (Mesalamine Plus N-acetylcysteine) in Subjects With Left-sided Ulcerative Colitis","status":"UNKNOWN","sponsor":"Altheus Therapeutics, Inc.","isPivotal":false,"enrollment":120,"indication":"Ulcerative Colitis, Left-sided Ulcerative Colitis","completionDate":""},{"nctId":"NCT01612247","phase":"NA","title":"Low Dose Metronomic Cyclophosphamide and Methotrexate Chemotherapy in Combination With Aspirin in Patients With Stage II-III Breast Cancer Who Fail to Achieve a Pathologic Complete Response After Neoa","status":"UNKNOWN","sponsor":"University of Vermont","isPivotal":false,"enrollment":13,"indication":"Breast Cancer","completionDate":"2014-02"},{"nctId":"NCT04499495","phase":"N/A","title":"A Retrospective Study to Assess 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","isPivotal":false,"enrollment":11385,"indication":"Ulcerative Colitis","completionDate":"2022-07-31"},{"nctId":"NCT05663775","phase":"Phase 2","title":"Prophylactic Oral Mesalamine for the Prevention of Immune-Related Colitis in Patients Treated With Ipilimumab/Nivolumab","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","isPivotal":false,"enrollment":20,"indication":"Immune-related Adverse Event, Diarrhea","completionDate":"2027-08"},{"nctId":"NCT03070574","phase":"Phase 2","title":"Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome - MesaCAPP","status":"TERMINATED","sponsor":"Christoph Gasche","isPivotal":false,"enrollment":8,"indication":"Colorectal Cancer","completionDate":"2019-04-10"},{"nctId":"NCT04034758","phase":"NA","title":"Safety and Efficacy of Heterologous Fecal Microbiota Transplantation (FMT) by Standardized Quantitative Multi-donor Intestinal Microbiota Capsule (SQIMC-md) in Mild-moderate Ulcerative Colitis Patient","status":"UNKNOWN","sponsor":"Tongji Hospital","isPivotal":false,"enrollment":99,"indication":"Ulcerative Colitis","completionDate":"2023-12-31"},{"nctId":"NCT00000796","phase":"NA","title":"A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment o","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":525,"indication":"HIV Infections, Tuberculosis","completionDate":"1998-10"},{"nctId":"NCT01320436","phase":"Phase 3","title":"Randomized, Double-blind, Placebo-controlled Study to Evaluated the Efficacy of Combining Curcumin+5ASA Medication Versus 5ASA Medication Alone on Active Mild to Moderate Ulcerative Colitis Patients","status":"COMPLETED","sponsor":"Sheba Medical Center","isPivotal":true,"enrollment":50,"indication":"Ulcerative Colitis","completionDate":"2014-10"},{"nctId":"NCT01020708","phase":"Phase 1","title":"A Phase I Double-blind, Randomized, Comparator-controlled Study of the Safety and Tolerability of N-acetylcysteine Plus Mesalamine Enema in Subjects With Left-sided Ulcerative Colitis","status":"COMPLETED","sponsor":"Altheus Therapeutics, Inc.","isPivotal":false,"enrollment":9,"indication":"Ulcerative Colitis","completionDate":"2010-09"},{"nctId":"NCT00514982","phase":"Phase 2","title":"An Observational Study of the Immunopathogenesis of and Response to Step-Up Inflammatory Bowel Disease Therapy for Hermansky-Pudlak Syndrome-Associated Colitis","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":0,"indication":"Hermanski-Pudlak Syndrome, Colitis","completionDate":"2011-03-08"},{"nctId":"NCT06895252","phase":"NA","title":"Efficacy of Microbiome Manipulation Strategies (fecAL Microbial Transplantation OR Anti-inflammatory diEt OR Both) in Combination With 5-aminosalicylic Acid for Induction and Maintenance of Remission ","status":"RECRUITING","sponsor":"All India Institute of Medical Sciences","isPivotal":false,"enrollment":220,"indication":"Ulcerative Colitis (UC)","completionDate":"2028-03-15"},{"nctId":"NCT00513396","phase":"Phase 2","title":"A Randomized Control Trial Of High-Dose Isoniazid Adjuvant Therapy For Multidrug Resistant Tuberculosis","status":"COMPLETED","sponsor":"GSVM Medical College","isPivotal":true,"enrollment":134,"indication":"Tuberculosis, Multidrug-Resistant","completionDate":"2006-12"},{"nctId":"NCT02537210","phase":"NA","title":"Oral 5-aminosalicylic Acid Withdrawal in Long Standing Inactive Ulcerative Colitis: A Double-blind, Randomized, Placebo-controlled Trial","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","isPivotal":false,"enrollment":177,"indication":"Colitis, Ulcerative, Aminosalicylic Acid","completionDate":"2021-09-10"},{"nctId":"NCT01941589","phase":"Phase 4","title":"Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis.","status":"COMPLETED","sponsor":"Sheba Medical Center","isPivotal":false,"enrollment":149,"indication":"Ulcerative Colitis","completionDate":"2021-04"},{"nctId":"NCT03980405","phase":"NA","title":"Combination Therapy With Drug and Diet for Induction of Remission in Mild to Moderate Active Pediatric Ulcerative Colitis: A Single Blinded, International Randomized Controlled Trial","status":"TERMINATED","sponsor":"Prof. Arie Levine","isPivotal":false,"enrollment":12,"indication":"Ulcerative Colitis","completionDate":"2022-05-30"},{"nctId":"NCT00417690","phase":"Phase 2","title":"A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an Acute Flare of Crohn's Disease","status":"TERMINATED","sponsor":"Jacobus Pharmaceutical","isPivotal":false,"enrollment":54,"indication":"Crohn's Disease","completionDate":"2008-10"},{"nctId":"NCT00004810","phase":"Phase 2","title":"","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","isPivotal":false,"enrollment":30,"indication":"Ulcerative Colitis","completionDate":""},{"nctId":"NCT02365623","phase":"Phase 2","title":"An Open-Label Study to Explore the Safety, Efficacy and Pharmacokinetics of TMC207 in Japanese Patients With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","isPivotal":false,"enrollment":6,"indication":"Tuberculosis, Multidrug-Resistant","completionDate":"2018-11-08"},{"nctId":"NCT00004423","phase":"NA","title":"","status":"COMPLETED","sponsor":"University of Vermont","isPivotal":false,"enrollment":80,"indication":"Crohn's Disease","completionDate":"1998-03"},{"nctId":"NCT01004185","phase":"Phase 3","title":"A Randomized, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8g/Day) 400 mg Delayed-release Tablets Given Twice Daily for 26 Weeks to Children and Adolescent","status":"TERMINATED","sponsor":"Warner Chilcott","isPivotal":true,"enrollment":39,"indication":"Ulcerative Colitis","completionDate":"2011-03"},{"nctId":"NCT02930343","phase":"Phase 3","title":"Comparison of Sulfasalazine Versus Leflunomide Based Combination Disease Modifying Anti-rheumatic Drug Therapy (DMARD) in Patients With Rheumatoid Arthritis Failing Methotrexate Monotherapy : A Random","status":"TERMINATED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","isPivotal":true,"enrollment":136,"indication":"Rheumatoid Arthritis","completionDate":"2018-08"},{"nctId":"NCT02128308","phase":"Phase 1","title":"A Open-label, Single Sequence Clinical Trial to Investigate the Pharmacokinetic Characteristics of Second-Line Anti-Tuberculosis Agents After Multiple Oral/Intramuscular Administration in Healthy Male","status":"COMPLETED","sponsor":"Seoul National University Hospital","isPivotal":false,"enrollment":16,"indication":"Healthy","completionDate":"2014-01"},{"nctId":"NCT05213234","phase":"NA","title":"Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis: A Randomized Crossover Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rush University Medical Center","isPivotal":false,"enrollment":32,"indication":"Ulcerative Colitis","completionDate":"2026-06-30"},{"nctId":"NCT07296315","phase":"Phase 2","title":"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Confirm Efficacy and Safety of MH002 and to Assess the Effect of Dose in Patients With Mild-to- Moderate Ulcerative Colitis Insufficient","status":"NOT_YET_RECRUITING","sponsor":"MRM Health NV","isPivotal":false,"enrollment":204,"indication":"Colitis, Ulcerative","completionDate":"2028-05"},{"nctId":"NCT04032652","phase":"Phase 2","title":"Measurement of Rectal Levels of 5-aminosalicylic Acid (5-ASA) Using a Novel In-vivo Rectal Dialysis Technique in Healthy Volunteers on Asacol","status":"TERMINATED","sponsor":"Endeavor Health","isPivotal":false,"enrollment":2,"indication":"Ulcerative Colitis","completionDate":"2014-12-05"},{"nctId":"NCT06213857","phase":"Phase 2","title":"Clinical Study Evaluating the Possible Beneficial Effect of Silymarin in Patients With Ulcerative Colitis","status":"RECRUITING","sponsor":"Tanta University","isPivotal":false,"enrollment":44,"indication":"Ulcerative Colitis","completionDate":"2025-06"},{"nctId":"NCT03070405","phase":"Phase 1","title":"An Open-label, Randomized, Crossover Study to Evaluate the Effect of PAS on the Pharmacokinetics of Tenofovir in Healthy Subjects","status":"UNKNOWN","sponsor":"Inje University","isPivotal":false,"enrollment":20,"indication":"Healthy Volunteers","completionDate":"2017-05"},{"nctId":"NCT01654783","phase":"N/A","title":"Observational Study on Clinical Practice in the Management of Ulcerative Colitis With Oral 5-Aminosalicylic Acid in Japan","status":"COMPLETED","sponsor":"Kyorin Pharmaceutical Co.,Ltd","isPivotal":false,"enrollment":5704,"indication":"Ulcerative Colitis","completionDate":"2014-06"},{"nctId":"NCT01577966","phase":"NA","title":"A Pilot Study to Determine the Effect of Sulfasalazine on Glutamate Levels Detected by Magnetic Resonance Spectroscopy(MRS) in Patients With Glioma","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","isPivotal":false,"enrollment":9,"indication":"Brain Tumor","completionDate":"2015-01"},{"nctId":"NCT00069498","phase":"Phase 1","title":"Impact of Co-Receptor and HIV Viral Burden on Gut Mucosa","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":14,"indication":"HIV Infections","completionDate":""},{"nctId":"NCT05610956","phase":"EARLY/Phase 1","title":"Clinical Study to Evaluate the Possible Efficacy and Safety of Empagliflozin in Patients With Ulcerative Colitis","status":"RECRUITING","sponsor":"Tanta University","isPivotal":false,"enrollment":60,"indication":"Ulcerative Colitis","completionDate":"2026-12-01"},{"nctId":"NCT05988528","phase":"Phase 2","title":"Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis","status":"COMPLETED","sponsor":"Mostafa Bahaa","isPivotal":true,"enrollment":50,"indication":"Inflammatory Bowel Diseases","completionDate":"2025-02-20"},{"nctId":"NCT01532648","phase":"Phase 3","title":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX® 9 mg Extended-release Tablets as Add-on Therapy in Patients With Active, Mild or Modera","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","isPivotal":true,"enrollment":510,"indication":"Ulcerative Colitis","completionDate":"2013-10-02"},{"nctId":"NCT02077777","phase":"Phase 2","title":"Azione Chemiopreventiva Della Mesalazina Sul Cancro Del Colon-retto: Studio Pilota Per la Valutazione Degli Effetti Molecolari \"in Vivo\" Sulla Via di Segnalazione Proliferativa Della β-catenina (Offic","status":"COMPLETED","sponsor":"SOFAR S.p.A.","isPivotal":false,"enrollment":21,"indication":"Colorectal Cancer","completionDate":"2016-06"},{"nctId":"NCT06998693","phase":"N/A","title":"A Single-Center Observational Study on the Impact of Symptom Assessment Timing on the Short-Term Efficacy of 5-ASA Therapy in Patients With Initial-Onset or Relapsed Mild-to-Moderate Active Ulcerative","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","isPivotal":false,"enrollment":180,"indication":"Ul","completionDate":"2025-09-30"},{"nctId":"NCT00495521","phase":"Phase 2","title":"A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an Acute Flare of Crohn's Disease","status":"TERMINATED","sponsor":"Jacobus Pharmaceutical","isPivotal":false,"enrollment":2,"indication":"Crohn's Disease","completionDate":"2008-10"},{"nctId":"NCT05986136","phase":"Phase 2","title":"Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Mostafa Bahaa","isPivotal":true,"enrollment":50,"indication":"Inflammatory Bowel Diseases","completionDate":"2028-07-20"},{"nctId":"NCT00984568","phase":"Phase 3","title":"Conventional Step-Up Versus Infliximab Monotherapy in Patients With Active Moderate to Severe Ulcerative Colitis. A Randomized, Open Label, Prospective, Multicenter Study","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"enrollment":28,"indication":"Colitis, Ulcerative","completionDate":"2012-03"},{"nctId":"NCT02975570","phase":"Phase 3","title":"Prospective, Randomized, Open Label Phase 3 Study of the Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin for Treatment of Patients With Fluoroquinolone-susceptible Mul","status":"WITHDRAWN","sponsor":"Boston University","isPivotal":true,"enrollment":0,"indication":"Tuberculosis Multi Drug Resistant Active","completionDate":"2022-08"},{"nctId":"NCT06201793","phase":"Phase 2","title":"Clinical Study to Evaluate the Possible Efficacy and Safety of Minocycline in Patients With Ulcerative Colitis Treated With Mesalamine","status":"COMPLETED","sponsor":"Mostafa Bahaa","isPivotal":false,"enrollment":46,"indication":"Inflammatory Bowel Diseases","completionDate":"2025-01-20"},{"nctId":"NCT01090102","phase":"Phase 4","title":"Mesalamine to Reduce T Cell Activation in HIV Infection","status":"COMPLETED","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":33,"indication":"HIV Infections, Sexually Transmitted Diseases","completionDate":"2012-12"},{"nctId":"NCT06081361","phase":"Phase 3","title":"A Multicenter, Randomized, Open-Label Study To Evaluate The Efficacy And Safety Of A Contezolid, Delamanid and Bedaquiline-Containing Short Regimen For The Treatment Of Rifampicin-Resistant Pulmonary ","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Chest Hospital","isPivotal":true,"enrollment":186,"indication":"Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","completionDate":"2026-12-31"},{"nctId":"NCT01860963","phase":"NA","title":"Prevalence of Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls","status":"COMPLETED","sponsor":"Stanford University","isPivotal":false,"enrollment":310,"indication":"Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA","completionDate":"2013-06"},{"nctId":"NCT07389824","phase":"NA","title":"Efficacy of Acupuncture Combined With Mesalazine in Inducing and Maintaining Clinical Remission in Mild-to-Moderate Active Ulcerative Colitis: A Single-Center, Randomized Controlled Clinical Trial.","status":"NOT_YET_RECRUITING","sponsor":"Qin Yu","isPivotal":false,"enrollment":80,"indication":"Ulcerative Colitis","completionDate":"2027-12-31"},{"nctId":"NCT03625739","phase":"N/A","title":"Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis","status":"RECRUITING","sponsor":"Beijing Children's Hospital","isPivotal":false,"enrollment":800,"indication":"Tuberculosis","completionDate":"2026-12-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"ORAL","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL1169"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"companyName":"BRISTOL MYERS SQUIBB","companyId":"bristol-myers-squibb","modality":"Small Molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"BRISTOL MYERS SQUIBB","brand_name_local":"REZIPAS","application_number":"NDA009052"}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:54:59.598088+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}